Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Invivocure LLC

Neither a doctor nor a teaching hospital

Research payments

$1,365,714

308 payments

Through program year 2025, Invivocure LLC is reported as receiving $1,365,714 in research payments, across 308 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $726,136 18
2024 Research $244,766 97
2023 Research $261,591 138
2022 Research $49,402 47
2021 Research $52,477 4
2020 Research $31,342 4

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $912,072 9 payments
  2. Applied Therapeutics, inc. $164,732 9 payments
  3. Alnylam Pharmaceuticals Inc. $163,461 279 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $125,451 11 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $583,524 5 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $328,547 4 payments
  3. Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy $164,732 9 payments
  4. Bmad $125,451 11 payments
  5. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $106,640 208 payments
  6. Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $22,671 9 payments
  7. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) $16,919 15 payments
  8. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $12,805 30 payments
  9. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) $4,426 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record